AdaptHealth (AHCO) Financials

$8.06 +0.33 (+4.27%)

As of 03:59 PM Eastern

Annual Income Statements for AdaptHealth

This table shows AdaptHealth's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	23	-21	-162	156	69	-679	90
Consolidated Net Income / (Loss)	24	-23	-194	158	73	-675	95
Net Income / (Loss) Continuing Operations	24	-23	-194	158	73	-675	95
Total Pre-Tax Income	22	-22	-206	191	98	-724	136
Total Operating Income	31	29	71	226	190	-598	264
Total Gross Profit	52	89	158	446	580	624	681
Total Revenue	361	530	1,056	2,455	2,971	3,200	3,261
Operating Revenue	361	530	1,056	2,455	2,971	3,200	3,261
Total Cost of Revenue	309	441	899	2,009	2,390	2,576	2,580
Operating Cost of Revenue	293	441	899	2,009	2,390	2,576	2,580
Total Operating Expenses	21	60	86	220	390	1,222	417
Selling, General & Admin Expense	18	56	89	168	325	335	359
Depreciation Expense	2.73	3.07	11	63	65	57	45
Impairment Charge	-	-	-	0.00	0.00	831	13
Total Other Income / (Expense), net	-8.85	-51	-277	-35	-93	-125	-128
Interest Expense	8.85	41	47	115	0.00	0.00	2.27
Interest & Investment Income	-	-	-	-	-109	-130	-127
Other Income / (Expense), net	-	-9.82	-231	81	17	4.92	1.23
Income Tax Expense	-2.10	0.74	-12	33	25	-49	41
Net Income / (Loss) Attributable to Noncontrolling Interest	1.08	-1.26	-32	1.98	3.82	4.12	4.36
Basic Earnings per Share	-	-	($3.08)	$1.12	$0.47	($5.06)	$0.62
Weighted Average Basic Shares Outstanding	11.90M	22.56M	52.49M	126.31M	134.18M	134.16M	133.76M
Diluted Earnings per Share	-	($0.95)	($3.08)	$0.67	$0.33	($5.31)	$0.61
Weighted Average Diluted Shares Outstanding	11.90M	22.56M	52.49M	133.03M	138.99M	134.42M	135.53M
Weighted Average Basic & Diluted Shares Outstanding	11.90M	22.56M	52.49M	133.91M	135.45M	132.91M	134.87M

This table shows AdaptHealth's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	16	-2.59	16	14	-454	-255	-2.13	19	23	50
Consolidated Net Income / (Loss)	17	-1.57	17	15	-453	-254	-1.11	21	24	51
Net Income / (Loss) Continuing Operations	17	-1.57	17	15	-453	-254	-1.11	21	24	51
Total Pre-Tax Income	23	3.16	15	20	-487	-272	5.50	28	32	71
Total Operating Income	53	27	26	54	-461	-218	51	52	63	98
Total Gross Profit	110	244	89	120	111	304	117	127	124	313
Total Revenue	756	780	745	793	804	858	792	806	806	857
Operating Revenue	756	780	745	793	804	858	792	806	806	857
Total Cost of Revenue	647	537	655	673	693	554	676	679	682	543
Operating Cost of Revenue	647	537	655	673	693	554	676	679	682	543
Total Operating Expenses	57	217	63	66	572	522	66	75	61	216
Selling, General & Admin Expense	41	200	48	50	45	192	48	57	49	205
Depreciation Expense	16	17	16	16	15	11	11	11	11	11
Total Other Income / (Expense), net	-30	-24	-11	-34	-26	-54	-45	-24	-31	-27
Interest Expense	29	-79	32	33	32	-97	32	33	34	-97
Other Income / (Expense), net	-1.62	6.94	21	-1.27	5.84	-20	-13	8.77	2.24	2.77
Income Tax Expense	5.58	4.73	-1.71	5.40	-35	-18	6.61	7.25	8.07	19
Net Income / (Loss) Attributable to Noncontrolling Interest	1.11	1.02	0.97	1.06	1.16	0.93	1.03	1.10	1.10	1.14
Basic Earnings per Share	$0.11	($0.03)	$0.11	$0.10	($3.37)	($1.90)	($0.02)	$0.13	$0.16	$0.35
Weighted Average Basic Shares Outstanding	134.23M	134.18M	134.53M	134.30M	134.83M	134.16M	132.91M	133.22M	134.30M	133.76M
Diluted Earnings per Share	$0.11	$0.05	($0.06)	$0.09	($3.43)	($1.91)	($0.02)	$0.13	$0.15	$0.35
Weighted Average Diluted Shares Outstanding	137.58M	138.99M	135.98M	136.23M	134.98M	134.42M	132.91M	136.03M	136.53M	135.53M
Weighted Average Basic & Diluted Shares Outstanding	134.73M	135.45M	134.17M	136.11M	136.39M	132.91M	133.20M	134.47M	134.55M	134.87M

This table details how cash moves in and out of AdaptHealth's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	21	52	23	50	-103	31	33
Net Cash From Operating Activities	68	60	196	276	374	481	542
Net Cash From Continuing Operating Activities	68	60	196	276	374	481	542
Net Income / (Loss) Continuing Operations	24	-23	-194	158	73	-675	95
Consolidated Net Income / (Loss)	24	-23	-194	158	73	-675	95
Depreciation Expense	48	63	82	258	351	383	365
Amortization Expense	0.48	1.31	1.88	5.38	5.23	5.23	5.67
Non-Cash Adjustments To Reconcile Net Income	18	22	252	-11	6.01	825	38
Changes in Operating Assets and Liabilities, net	-22	-2.52	53	-135	-62	-57	39
Net Cash From Investing Activities	-96	-85	-816	-1,825	-411	-357	-310
Net Cash From Continuing Investing Activities	-96	-85	-816	-1,825	-411	-357	-310
Purchase of Property, Plant & Equipment	-9.95	-21	-40	-203	-391	-337	-306
Acquisitions	-86	-64	-769	-1,620	-19	-20	-9.54
Purchase of Investments	-	0.00	-8.66	-1.13	-0.73	-0.13	0.00
Sale of Property, Plant & Equipment	-	-	-	-	0.00	0.00	5.32
Net Cash From Financing Activities	49	76	643	1,599	-66	-93	-199
Net Cash From Continuing Financing Activities	49	76	643	1,599	-66	-93	-199
Repayment of Debt	-116	-164	-561	-914	-36	-100	-430
Repurchase of Common Equity	0.00	-25	-12	-14	-14	-29	0.00
Payment of Dividends	-0.30	-251	-0.80	-1.07	-2.00	-2.50	-5.60
Issuance of Debt	165	361	941	2,265	1.62	50	254
Other Financing Activities, net	0.00	30	-93	-16	-15	-11	-18
Cash Interest Paid	7.33	23	36	74	109	126	122
Cash Income Taxes Paid	0.41	1.32	7.48	15	15	15	14

This table details how cash moves in and out of AdaptHealth's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-8.07	-64	55	-56	11	21	2.43	-9.73	30	9.57
Net Cash From Operating Activities	107	97	140	86	99	155	49	198	144	150
Net Cash From Continuing Operating Activities	107	97	140	86	99	155	49	198	144	150
Net Income / (Loss) Continuing Operations	17	-1.57	17	15	-453	-254	-1.11	21	24	51
Consolidated Net Income / (Loss)	17	-1.57	17	15	-453	-254	-1.11	21	24	51
Depreciation Expense	92	102	94	99	97	92	93	91	91	91
Amortization Expense	1.31	1.31	1.31	1.31	1.31	1.31	1.31	1.42	1.52	1.42
Non-Cash Adjustments To Reconcile Net Income	7.22	8.26	-17	9.71	507	324	19	7.10	3.83	7.57
Changes in Operating Assets and Liabilities, net	-11	-13	45	-39	-54	-8.90	-63	78	24	-0.51
Net Cash From Investing Activities	-95	-146	-90	-100	-77	-90	-88	-81	-54	-87
Net Cash From Continuing Investing Activities	-95	-146	-90	-100	-77	-90	-88	-81	-54	-87
Purchase of Property, Plant & Equipment	-94	-143	-89	-83	-77	-89	-88	-81	-60	-77
Acquisitions	-0.81	-2.88	-0.45	-17	-0.01	-1.77	0.00	-	-	-9.54
Net Cash From Financing Activities	-20	-16	4.45	-42	-11	-44	41	-126	-60	-54
Net Cash From Continuing Financing Activities	-20	-16	4.45	-42	-11	-44	41	-126	-60	-54
Repayment of Debt	-5.81	-8.57	-31	-37	-9.87	-22	-27	-123	-230	-50
Payment of Dividends	-	-	-	-	-	-	-	-	-	-2.10
Other Financing Activities, net	-3.32	-8.63	-6.37	-2.20	-0.85	-1.60	-7.03	-0.35	-8.67	-1.88
Cash Interest Paid	47	11	50	13	50	13	50	13	49	9.55
Cash Income Taxes Paid	0.66	4.46	0.38	5.18	0.16	9.03	-0.33	12	0.92	1.12

This table presents AdaptHealth's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	0.31	369	547	1,813	5,250	5,220	4,509	4,487
Total Current Assets	0.12	91	181	363	670	585	649	756
Cash & Equivalents	0.12	25	77	100	150	46	77	110
Accounts Receivable	-	53	79	171	360	359	389	408
Inventories, net	-	7.67	13	59	123	128	114	140
Prepaid Expenses	0.00	4.92	13	33	37	52	69	45
Other Current Nonoperating Assets	-	-	-	-	-	-	0.00	53
Plant, Property, & Equipment, net	0.00	62	64	110	399	487	495	475
Total Noncurrent Assets	0.19	217	302	1,340	4,182	4,142	3,333	3,219
Goodwill	-	202	267	999	3,513	3,545	2,725	2,675
Intangible Assets	-	-	0.00	116	202	163	130	106
Noncurrent Deferred & Refundable Income Taxes	-	9.08	28	208	304	282	346	315
Other Noncurrent Operating Assets	0.19	5.05	6.85	16	163	152	132	124
Total Liabilities & Shareholders' Equity	0.31	369	547	1,813	5,250	5,220	4,509	4,487
Total Liabilities	0.29	266	612	1,533	3,184	3,062	3,042	2,909
Total Current Liabilities	0.29	136	154	422	500	456	537	567
Short-Term Debt	0.17	28	21	8.15	20	35	53	16
Accounts Payable	0.06	86	103	254	358	337	392	438
Current Deferred Revenue	-	-	9.56	11	31	32	39	35
Other Current Liabilities	0.00	22	20	149	90	52	49	71
Other Current Nonoperating Liabilities	-	-	-	-	-	-	0.00	7.04
Total Noncurrent Liabilities	0.00	233	458	1,111	2,684	2,602	2,505	2,342
Long-Term Debt	-	127	395	777	2,184	2,153	2,095	1,965
Other Noncurrent Operating Liabilities	0.00	106	63	334	500	448	410	377
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.02	0.00	-66	281	2,067	2,158	1,467	1,578
Total Preferred & Common Equity	0.02	0.00	-39	355	2,062	2,151	1,458	1,571
Preferred Stock	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	0.02	0.00	-39	355	2,062	2,151	1,458	1,571
Common Stock	0.03	0.00	0.01	558	2,107	2,130	2,150	2,157
Retained Earnings	-0.00	0.00	-40	-199	-43	26	-653	-562
Treasury Stock	-	-	-	-	0.00	-14	-43	-26
Accumulated Other Comprehensive Income / (Loss)	-	0.00	1.43	-4.41	-2.35	8.69	4.36	2.25
Noncontrolling Interest	-	0.00	-27	-74	4.78	6.60	8.22	6.97

This table presents AdaptHealth's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	5,238	5,283	5,203	4,725	4,504	4,511	4,470
Total Current Assets	632	647	568	585	656	686	684
Cash & Equivalents	111	101	45	56	80	70	100
Accounts Receivable	358	353	366	371	430	437	401
Inventories, net	125	136	115	116	109	124	133
Prepaid Expenses	37	56	43	42	38	56	49
Plant, Property, & Equipment, net	473	503	504	490	0.00	496	475
Total Noncurrent Assets	4,133	4,126	4,116	3,629	3,848	3,291	3,272
Goodwill	3,525	3,545	3,552	3,041	2,718	2,712	2,707
Intangible Assets	173	153	143	136	125	119	113
Noncurrent Deferred & Refundable Income Taxes	286	285	280	319	341	334	328
Other Noncurrent Operating Assets	149	143	140	133	633	126	124
Total Liabilities & Shareholders' Equity	5,238	5,283	5,203	4,725	4,504	4,511	4,470
Total Liabilities	3,078	3,116	3,016	2,985	3,033	3,018	2,946
Total Current Liabilities	467	524	458	448	493	596	553
Short-Term Debt	59	40	40	40	81	40	16
Accounts Payable	347	401	338	314	340	447	430
Current Deferred Revenue	32	32	35	48	-	36	36
Other Current Liabilities	30	51	46	46	72	69	68
Total Noncurrent Liabilities	2,611	2,586	2,547	2,522	2,540	2,422	2,393
Long-Term Debt	2,162	2,169	2,136	2,127	2,159	2,040	2,014
Other Noncurrent Operating Liabilities	449	417	412	395	276	382	379
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,160	2,167	2,187	1,740	1,471	1,493	1,524
Total Preferred & Common Equity	2,154	2,160	2,181	1,732	1,462	1,486	1,516
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,154	2,160	2,181	1,732	1,462	1,486	1,516
Common Stock	2,126	2,135	2,140	2,145	2,155	2,160	2,153
Retained Earnings	29	42	56	-398	-655	-635	-612
Treasury Stock	-14	-23	-23	-23	-43	-43	-26
Accumulated Other Comprehensive Income / (Loss)	13	5.89	8.34	8.41	5.21	4.85	1.63
Noncontrolling Interest	5.58	7.57	6.13	7.29	9.24	6.84	7.93

This table displays calculated financial ratios and metrics derived from AdaptHealth's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	46.69%	99.45%	132.35%	21.02%	7.73%	1.90%
EBITDA Growth	0.00%	5.03%	-189.85%	859.96%	-1.06%	-136.45%	409.52%
EBIT Growth	0.00%	-37.08%	-914.27%	292.31%	-32.33%	-386.27%	144.64%
NOPAT Growth	0.00%	-39.56%	142.86%	274.13%	-23.87%	-394.49%	143.87%
Net Income Growth	0.00%	-192.87%	-758.75%	181.49%	-53.76%	-1,022.68%	114.05%
EPS Growth	0.00%	0.00%	-224.21%	121.75%	-50.75%	-1,709.09%	111.49%
Operating Cash Flow Growth	0.00%	-11.70%	223.80%	40.92%	35.62%	28.57%	12.73%
Free Cash Flow Firm Growth	0.00%	0.00%	-420.16%	-362.52%	98.81%	1,143.85%	-11.49%
Invested Capital Growth	0.00%	110.73%	252.51%	326.74%	4.31%	-18.35%	-4.09%
Revenue Q/Q Growth	0.00%	-28.54%	23.19%	16.83%	2.70%	2.50%	-0.05%
EBITDA Q/Q Growth	0.00%	37.18%	-165.50%	63.84%	-0.06%	-369.00%	112.67%
EBIT Q/Q Growth	0.00%	-67.84%	-525.42%	122.66%	-10.93%	-84.53%	459.61%
NOPAT Q/Q Growth	0.00%	-58.72%	90.54%	32.42%	-20.18%	-69.10%	607.42%
Net Income Q/Q Growth	0.00%	-278.31%	-67.40%	258.06%	-25.51%	-59.61%	145.09%
EPS Q/Q Growth	0.00%	0.00%	0.00%	155.37%	-53.52%	-58.51%	136.97%
Operating Cash Flow Q/Q Growth	0.00%	-46.47%	20.37%	22.47%	-1.06%	13.82%	-0.89%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.84%	-5.79%	84.38%	107.91%	-16.27%
Invested Capital Q/Q Growth	0.00%	11.84%	5.15%	6.61%	0.66%	-8.71%	-1.50%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	14.37%	16.79%	14.94%	18.15%	19.53%	19.50%	20.89%
EBITDA Margin	22.00%	15.75%	-7.10%	23.21%	18.98%	-6.42%	19.50%
Operating Margin	8.61%	5.55%	6.75%	9.19%	6.41%	-18.70%	8.09%
EBIT Margin	8.61%	3.69%	-15.08%	12.48%	6.98%	-18.55%	8.13%
Profit (Net Income) Margin	6.74%	-4.27%	-18.37%	6.44%	2.46%	-21.09%	2.91%
Tax Burden Percent	109.43%	103.38%	94.20%	82.82%	74.70%	93.23%	69.68%
Interest Burden Percent	71.53%	-111.75%	129.35%	62.34%	47.22%	121.95%	51.34%
Effective Tax Rate	-9.43%	0.00%	0.00%	17.18%	25.30%	0.00%	30.32%
Return on Invested Capital (ROIC)	26.17%	10.18%	8.06%	7.35%	3.38%	-10.73%	5.35%
ROIC Less NNEP Spread (ROIC-NNEP)	18.72%	-8.20%	-39.58%	5.25%	0.08%	-22.96%	0.70%
Return on Net Nonoperating Assets (RNNOA)	0.00%	58.53%	-188.55%	6.13%	0.08%	-26.51%	0.88%
Return on Equity (ROE)	0.00%	68.71%	-180.49%	13.47%	3.46%	-37.24%	6.23%
Cash Return on Invested Capital (CROIC)	0.00%	-61.09%	-103.55%	-116.71%	-0.84%	9.47%	9.52%
Operating Return on Assets (OROA)	16.84%	4.27%	-13.50%	8.67%	3.96%	-12.20%	5.89%
Return on Assets (ROA)	13.18%	-4.94%	-16.45%	4.48%	1.40%	-13.87%	2.11%
Return on Common Equity (ROCE)	0.00%	40.55%	-265.26%	13.87%	3.45%	-37.08%	6.19%
Return on Equity Simple (ROE_SIMPLE)	0.00%	58.22%	-54.69%	7.67%	3.40%	-46.27%	6.03%
Net Operating Profit after Tax (NOPAT)	34	21	50	187	142	-419	184
NOPAT Margin	9.42%	3.88%	4.73%	7.61%	4.79%	-13.09%	5.64%
Net Nonoperating Expense Percent (NNEP)	7.45%	18.38%	47.64%	2.10%	3.30%	12.23%	4.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	3.27%	-11.59%	5.16%
Cost of Revenue to Revenue	85.63%	83.21%	85.06%	81.85%	80.47%	80.50%	79.11%
SG&A Expenses to Revenue	5.00%	10.67%	8.46%	6.82%	10.93%	10.46%	11.02%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	5.76%	11.25%	8.18%	8.96%	13.12%	38.20%	12.80%
Earnings before Interest and Taxes (EBIT)	31	20	-159	306	207	-593	265
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	79	83	-75	570	564	-205	636
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	9.49	1.57	1.20	0.68	0.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.85	0.65	3.19	1.32	0.87	0.31	0.39
Price to Earnings (P/E)	13.21	0.00	0.00	20.71	37.36	0.00	14.17
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.57%	0.00%	0.00%	4.83%	2.68%	0.00%	7.06%
Enterprise Value to Invested Capital (EV/IC)	3.36	2.39	4.12	1.28	1.10	0.88	0.94
Enterprise Value to Revenue (EV/Rev)	1.21	1.24	3.77	2.16	1.60	0.96	0.97
Enterprise Value to EBITDA (EV/EBITDA)	5.50	7.86	0.00	9.29	8.41	0.00	4.97
Enterprise Value to EBIT (EV/EBIT)	14.06	33.53	0.00	17.28	22.85	0.00	11.92
Enterprise Value to NOPAT (EV/NOPAT)	12.85	31.89	79.64	28.33	33.31	0.00	17.19
Enterprise Value to Operating Cash Flow (EV/OCF)	6.39	10.86	20.33	19.20	12.67	6.39	5.83
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	8.31	9.65
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	-6.33	2.79	1.07	1.01	1.46	1.26
Long-Term Debt to Equity	0.00	-6.01	2.77	1.06	1.00	1.43	1.25
Financial Leverage	0.00	-7.14	4.76	1.17	0.99	1.15	1.26
Leverage Ratio	15,191.81	-13.92	10.97	3.01	2.48	2.68	2.95
Compound Leverage Factor	10,866.68	15.55	14.19	1.88	1.17	3.27	1.52
Debt to Total Capital	100.00%	118.75%	73.64%	51.60%	50.35%	59.42%	55.66%
Short-Term Debt to Total Capital	17.98%	6.12%	0.76%	0.47%	0.81%	1.48%	0.46%
Long-Term Debt to Total Capital	82.02%	112.63%	72.88%	51.13%	49.55%	57.95%	55.21%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-7.69%	-6.95%	0.11%	0.15%	0.23%	0.20%
Common Equity to Total Capital	0.00%	-11.07%	33.31%	48.29%	49.50%	40.35%	44.14%
Debt to EBITDA	1.95	4.99	-10.47	3.87	3.88	-10.45	3.12
Net Debt to EBITDA	1.64	4.07	-9.13	3.60	3.80	-10.08	2.94
Long-Term Debt to EBITDA	1.60	4.74	-10.36	3.83	3.82	-10.19	3.09
Debt to NOPAT	4.56	20.26	15.71	11.79	15.38	-5.13	10.78
Net Debt to NOPAT	3.82	16.52	13.71	10.99	15.06	-4.94	10.18
Long-Term Debt to NOPAT	3.74	19.21	15.55	11.69	15.14	-5.00	10.69
Altman Z-Score	1.80	1.38	1.42	1.30	1.24	0.30	1.06
Noncontrolling Interest Sharing Ratio	0.00%	40.99%	-46.97%	-2.95%	0.27%	0.41%	0.50%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.67	1.18	0.86	1.34	1.28	1.21	1.33
Quick Ratio	0.58	1.01	0.64	1.02	0.89	0.87	0.91
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-123	-642	-2,968	-35	370	327
Operating Cash Flow to CapEx	687.71%	283.23%	492.10%	135.60%	95.51%	142.44%	180.17%
Free Cash Flow to Firm to Interest Expense	0.00	-2.98	-13.73	-25.72	0.00	0.00	144.00
Operating Cash Flow to Interest Expense	7.73	1.46	4.19	2.39	0.00	0.00	238.38
Operating Cash Flow Less CapEx to Interest Expense	6.61	0.94	3.33	0.63	0.00	0.00	106.07
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	1.96	1.16	0.90	0.69	0.57	0.66	0.73
Accounts Receivable Turnover	0.00	8.05	8.46	9.25	8.26	8.56	8.18
Inventory Turnover	0.00	42.15	24.95	22.09	19.06	21.34	20.36
Fixed Asset Turnover	0.00	8.46	12.14	9.64	6.71	6.52	6.73
Accounts Payable Turnover	7.22	4.68	5.04	6.56	6.87	7.06	6.22
Days Sales Outstanding (DSO)	0.00	45.36	43.14	39.48	44.17	42.66	44.60
Days Inventory Outstanding (DIO)	0.00	8.66	14.63	16.52	19.15	17.10	17.93
Days Payable Outstanding (DPO)	50.54	77.97	72.49	55.65	53.13	51.68	58.71
Cash Conversion Cycle (CCC)	-50.54	-23.95	-14.73	0.35	10.20	8.08	3.82
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	130	274	966	4,121	4,298	3,510	3,366
Invested Capital Turnover	2.78	2.62	1.70	0.97	0.71	0.82	0.95
Increase / (Decrease) in Invested Capital	0.00	144	692	3,155	178	-789	-144
Enterprise Value (EV)	437	656	3,977	5,293	4,738	3,073	3,159
Market Capitalization	307	343	3,367	3,234	2,590	994	1,281
Book Value per Share	$0.00	($1.24)	$3.96	$15.60	$15.97	$10.69	$11.68
Tangible Book Value per Share	($6.48)	($9.78)	($8.48)	($12.50)	($11.56)	($10.24)	($8.99)
Total Capital	155	351	1,066	4,270	4,346	3,615	3,559
Total Debt	155	417	785	2,204	2,188	2,148	1,981
Total Long-Term Debt	127	395	777	2,184	2,153	2,095	1,965
Net Debt	130	340	685	2,054	2,142	2,071	1,871
Capital Expenditures (CapEx)	9.95	21	40	203	391	337	301
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-42	-28	-151	41	118	88	95
Debt-free Net Working Capital (DFNWC)	-17	49	-51	190	164	165	205
Net Working Capital (NWC)	-45	27	-59	170	129	112	189
Net Nonoperating Expense (NNE)	9.69	43	244	29	69	256	89
Net Nonoperating Obligations (NNO)	130	340	685	2,054	2,141	2,043	1,788
Total Depreciation and Amortization (D&A)	48	64	84	263	356	388	371
Debt-free, Cash-free Net Working Capital to Revenue	-11.68%	-5.29%	-14.26%	1.65%	3.97%	2.76%	2.92%
Debt-free Net Working Capital to Revenue	-4.70%	9.22%	-4.80%	7.75%	5.52%	5.17%	6.29%
Net Working Capital to Revenue	-12.43%	5.17%	-5.57%	6.94%	4.35%	3.50%	5.79%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	$0.00	$0.00	$0.00	$0.47	($5.06)	$0.62
Adjusted Weighted Average Basic Shares Outstanding	31.25M	73.31M	0.00	126.31M	134.18M	134.16M	133.76M
Adjusted Diluted Earnings per Share	($0.13)	$0.00	$0.00	$0.67	$0.33	($5.31)	$0.61
Adjusted Weighted Average Diluted Shares Outstanding	31.25M	73.31M	0.00	133.03M	138.99M	134.42M	135.53M
Adjusted Basic & Diluted Earnings per Share	($0.13)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.25M	22.56M	0.00	133.91M	135.45M	132.91M	134.87M
Normalized Net Operating Profit after Tax (NOPAT)	22	21	50	187	142	163	193
Normalized NOPAT Margin	6.03%	3.88%	4.73%	7.61%	4.79%	5.08%	5.92%
Pre Tax Income Margin	6.16%	-4.13%	-19.50%	7.78%	3.30%	-22.62%	4.17%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	3.51	0.47	-3.41	2.66	0.00	0.00	116.57
NOPAT to Interest Expense	3.84	0.50	1.07	1.62	0.00	0.00	80.85
EBIT Less CapEx to Interest Expense	2.39	-0.04	-4.26	0.89	0.00	0.00	-15.74
NOPAT Less CapEx to Interest Expense	2.72	-0.02	0.22	-0.14	0.00	0.00	-51.46
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	1.23%	-1,112.07%	-0.41%	0.68%	2.73%	-0.37%	5.91%
Augmented Payout Ratio	1.23%	-1,220.69%	-6.45%	9.42%	21.87%	-4.71%	5.91%

This table displays calculated financial ratios and metrics derived from AdaptHealth's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	15.80%	11.13%	5.44%	9.03%	6.28%	9.99%	6.43%	1.60%	0.23%	-0.19%
EBITDA Growth	-16.92%	-0.23%	-5.90%	17.71%	-345.97%	-205.25%	-6.96%	-0.13%	144.31%	233.12%
EBIT Growth	-50.12%	-43.03%	-35.39%	6.61%	-986.83%	-807.43%	-19.06%	14.77%	114.44%	142.17%
NOPAT Growth	-36.16%	-127.44%	-35.90%	6.65%	-906.93%	-1,047.94%	-134.92%	-3.66%	114.71%	146.57%
Net Income Growth	-70.43%	-106.69%	-60.51%	-1.35%	-2,729.13%	-16,040.99%	-106.65%	36.50%	105.29%	120.27%
EPS Growth	-45.00%	-88.37%	-175.00%	0.00%	-3,218.18%	-3,920.00%	66.67%	44.44%	104.37%	118.32%
Operating Cash Flow Growth	294.54%	-3.97%	111.05%	-16.58%	-7.65%	60.20%	-65.04%	129.36%	46.11%	-3.12%
Free Cash Flow Firm Growth	87.34%	93.85%	93.88%	89.61%	128.18%	433.20%	1,315.42%	1,603.06%	361.42%	-66.28%
Invested Capital Growth	10.48%	4.31%	1.73%	2.34%	-9.97%	-18.35%	-12.56%	-19.55%	-11.11%	-4.09%
Revenue Q/Q Growth	3.97%	3.14%	-4.57%	6.53%	1.35%	6.74%	-7.66%	1.70%	-0.01%	6.30%
EBITDA Q/Q Growth	11.10%	-5.27%	3.43%	8.14%	-332.15%	59.47%	191.44%	16.07%	3.00%	21.76%
EBIT Q/Q Growth	3.26%	-34.40%	39.34%	12.95%	-958.98%	47.67%	115.94%	60.16%	8.08%	52.81%
NOPAT Q/Q Growth	6.82%	-133.21%	319.67%	36.86%	-908.24%	52.76%	93.32%	477.61%	23.44%	49.52%
Net Income Q/Q Growth	12.99%	-109.12%	1,161.43%	-9.80%	-3,111.24%	44.01%	99.56%	1,951.31%	16.68%	114.58%
EPS Q/Q Growth	22.22%	-54.55%	-220.00%	250.00%	-3,911.11%	44.31%	98.95%	750.00%	15.38%	133.33%
Operating Cash Flow Q/Q Growth	3.43%	-9.44%	44.70%	-38.45%	14.50%	57.10%	-68.42%	303.76%	-27.06%	4.16%
Free Cash Flow Firm Q/Q Growth	35.34%	47.68%	77.31%	-35.38%	275.33%	518.56%	-14.15%	67.42%	-46.18%	-54.80%
Invested Capital Q/Q Growth	1.31%	0.66%	-0.58%	0.93%	-10.87%	-8.71%	5.78%	-7.13%	-1.52%	-1.50%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	14.51%	31.23%	11.98%	15.11%	13.75%	35.47%	14.74%	15.76%	15.39%	36.57%
EBITDA Margin	19.16%	17.60%	19.08%	19.36%	-44.35%	-16.84%	16.68%	19.03%	19.61%	22.46%
Operating Margin	7.00%	3.43%	3.52%	6.84%	-57.34%	-25.38%	6.38%	6.46%	7.88%	11.40%
EBIT Margin	6.79%	4.32%	6.30%	6.68%	-56.61%	-27.75%	4.79%	7.55%	8.16%	11.72%
Profit (Net Income) Margin	2.28%	-0.20%	2.24%	1.90%	-56.33%	-29.55%	-0.14%	2.55%	2.97%	6.00%
Tax Burden Percent	75.53%	-49.68%	111.46%	73.59%	92.91%	93.33%	-20.16%	73.91%	74.79%	72.69%
Interest Burden Percent	44.43%	9.39%	31.89%	38.57%	107.10%	114.06%	14.49%	45.68%	48.73%	70.40%
Effective Tax Rate	24.47%	149.68%	-11.46%	26.41%	0.00%	0.00%	120.16%	26.09%	25.21%	27.31%
Return on Invested Capital (ROIC)	3.76%	-1.20%	2.78%	3.63%	-30.89%	-14.56%	-1.04%	4.00%	5.29%	7.86%
ROIC Less NNEP Spread (ROIC-NNEP)	2.62%	-0.64%	2.19%	2.45%	-37.07%	-19.40%	-0.63%	3.12%	4.12%	6.84%
Return on Net Nonoperating Assets (RNNOA)	2.51%	-0.64%	2.13%	2.38%	-40.06%	-22.39%	-0.75%	3.48%	5.04%	8.60%
Return on Equity (ROE)	6.27%	-1.84%	4.92%	6.01%	-70.95%	-36.95%	-1.80%	7.48%	10.34%	16.47%
Cash Return on Invested Capital (CROIC)	-5.58%	-0.84%	1.14%	0.59%	4.38%	9.47%	3.37%	11.30%	10.77%	9.52%
Operating Return on Assets (OROA)	3.76%	2.45%	3.62%	3.95%	-35.48%	-18.26%	3.18%	5.07%	5.79%	8.50%
Return on Assets (ROA)	1.26%	-0.11%	1.29%	1.12%	-35.31%	-19.44%	-0.09%	1.71%	2.11%	4.35%
Return on Common Equity (ROCE)	6.25%	-1.83%	4.90%	5.99%	-70.71%	-36.80%	-1.79%	7.46%	10.29%	16.38%
Return on Equity Simple (ROE_SIMPLE)	4.56%	0.00%	2.20%	2.17%	-24.40%	0.00%	-47.38%	-46.24%	-13.86%	0.00%
Net Operating Profit after Tax (NOPAT)	40	-13	29	40	-323	-152	-10	38	47	71
NOPAT Margin	5.29%	-1.70%	3.92%	5.03%	-40.14%	-17.76%	-1.29%	4.77%	5.89%	8.29%
Net Nonoperating Expense Percent (NNEP)	1.14%	-0.56%	0.60%	1.18%	6.18%	4.83%	-0.42%	0.87%	1.18%	1.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.31%	-	-	-	-4.22%	-	-	-	1.99%
Cost of Revenue to Revenue	85.49%	68.77%	88.02%	84.89%	86.25%	64.53%	85.26%	84.24%	84.61%	63.43%
SG&A Expenses to Revenue	5.38%	25.65%	6.38%	6.31%	5.62%	22.35%	6.10%	7.07%	6.11%	23.88%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	7.51%	27.80%	8.47%	8.27%	71.09%	60.85%	8.36%	9.30%	7.51%	25.17%
Earnings before Interest and Taxes (EBIT)	51	34	47	53	-455	-238	38	61	66	100
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	145	137	142	154	-357	-145	132	153	158	192
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.17	1.20	0.78	0.75	0.71	0.68	1.07	0.90	1.00	0.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.87	0.87	0.56	0.53	0.40	0.31	0.48	0.41	0.46	0.39
Price to Earnings (P/E)	26.63	37.36	38.91	37.78	0.00	0.00	0.00	0.00	0.00	14.17
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.75%	2.68%	2.57%	2.65%	0.00%	0.00%	0.00%	0.00%	0.00%	7.06%
Enterprise Value to Invested Capital (EV/IC)	1.09	1.10	0.89	0.87	0.87	0.88	1.03	0.97	1.01	0.94
Enterprise Value to Revenue (EV/Rev)	1.60	1.60	1.26	1.23	1.08	0.96	1.18	1.03	1.06	0.97
Enterprise Value to EBITDA (EV/EBITDA)	8.23	8.41	6.85	6.52	43.94	0.00	0.00	0.00	11.53	4.97
Enterprise Value to EBIT (EV/EBIT)	19.94	22.85	20.92	20.39	0.00	0.00	0.00	0.00	0.00	11.92
Enterprise Value to NOPAT (EV/NOPAT)	26.05	33.31	31.47	30.50	0.00	0.00	0.00	0.00	0.00	17.19
Enterprise Value to Operating Cash Flow (EV/OCF)	12.28	12.67	8.49	8.76	7.95	6.39	9.87	6.68	6.31	5.83
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	78.76	150.76	18.87	8.31	28.47	7.61	8.82	9.65
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.03	1.01	1.02	0.99	1.25	1.46	1.59	1.39	1.33	1.26
Long-Term Debt to Equity	1.00	1.00	1.00	0.98	1.22	1.43	1.54	1.37	1.32	1.25
Financial Leverage	0.96	0.99	0.98	0.97	1.08	1.15	1.20	1.12	1.22	1.26
Leverage Ratio	2.51	2.48	2.45	2.41	2.55	2.68	2.69	2.64	2.82	2.95
Compound Leverage Factor	1.12	0.23	0.78	0.93	2.74	3.06	0.39	1.21	1.37	2.08
Debt to Total Capital	50.70%	50.35%	50.48%	49.87%	55.47%	59.42%	61.45%	58.23%	57.11%	55.66%
Short-Term Debt to Total Capital	1.34%	0.81%	0.91%	0.92%	1.02%	1.48%	2.12%	1.12%	0.46%	0.46%
Long-Term Debt to Total Capital	49.35%	49.55%	49.57%	48.95%	54.44%	57.95%	59.34%	57.11%	56.66%	55.21%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.13%	0.15%	0.17%	0.14%	0.19%	0.23%	0.24%	0.19%	0.22%	0.20%
Common Equity to Total Capital	49.18%	49.50%	49.35%	49.99%	44.35%	40.35%	38.31%	41.58%	42.66%	44.14%
Debt to EBITDA	3.94	3.88	3.98	3.76	28.37	-10.45	-10.89	-9.65	6.79	3.12
Net Debt to EBITDA	3.74	3.80	3.80	3.69	27.63	-10.08	-10.52	-9.33	6.45	2.94
Long-Term Debt to EBITDA	3.83	3.82	3.91	3.70	27.84	-10.19	-10.51	-9.47	6.73	3.09
Debt to NOPAT	12.46	15.38	18.30	17.60	-8.75	-5.13	-5.84	-5.16	-56.05	10.78
Net Debt to NOPAT	11.84	15.06	17.46	17.24	-8.52	-4.94	-5.64	-4.98	-53.28	10.18
Long-Term Debt to NOPAT	12.13	15.14	17.97	17.28	-8.59	-5.00	-5.64	-5.06	-55.60	10.69
Altman Z-Score	1.12	1.13	0.96	0.99	0.51	0.56	0.90	0.86	0.93	0.94
Noncontrolling Interest Sharing Ratio	0.24%	0.27%	0.30%	0.25%	0.33%	0.41%	0.46%	0.35%	0.47%	0.50%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.35	1.28	1.23	1.24	1.31	1.21	1.33	1.15	1.24	1.33
Quick Ratio	1.00	0.89	0.87	0.90	0.95	0.87	1.03	0.85	0.91	0.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-365	-191	-43	-59	103	636	527	882	475	215
Operating Cash Flow to CapEx	113.65%	67.82%	157.37%	104.49%	128.21%	175.15%	55.79%	243.61%	242.47%	194.50%
Free Cash Flow to Firm to Interest Expense	-12.80	0.00	-1.36	-1.80	3.18	0.00	16.22	26.69	14.08	0.00
Operating Cash Flow to Interest Expense	3.75	0.00	4.39	2.65	3.06	0.00	1.51	5.99	4.28	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.45	0.00	1.60	0.11	0.67	0.00	-1.20	3.53	2.52	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.55	0.57	0.57	0.59	0.63	0.66	0.66	0.67	0.71	0.73
Accounts Receivable Turnover	8.20	8.26	8.32	8.53	8.56	8.56	8.30	8.12	8.45	8.18
Inventory Turnover	21.71	19.06	22.16	24.59	22.52	21.34	22.41	23.00	21.89	20.36
Fixed Asset Turnover	7.10	6.71	6.48	6.41	6.48	6.52	0.00	6.52	6.76	6.73
Accounts Payable Turnover	7.42	6.87	7.28	8.20	8.23	7.06	7.39	7.00	7.34	6.22
Days Sales Outstanding (DSO)	44.54	44.17	43.86	42.80	42.62	42.66	43.98	44.93	43.18	44.60
Days Inventory Outstanding (DIO)	16.81	19.15	16.47	14.84	16.21	17.10	16.29	15.87	16.67	17.93
Days Payable Outstanding (DPO)	49.20	53.13	50.14	44.53	44.35	51.68	49.38	52.11	49.70	58.71
Cash Conversion Cycle (CCC)	12.15	10.20	10.19	13.11	14.47	8.08	10.89	8.68	10.15	3.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,270	4,298	4,273	4,313	3,844	3,510	3,737	3,470	3,417	3,366
Invested Capital Turnover	0.71	0.71	0.71	0.72	0.77	0.82	0.81	0.84	0.90	0.95
Increase / (Decrease) in Invested Capital	405	178	73	99	-426	-789	-537	-843	-427	-144
Enterprise Value (EV)	4,642	4,738	3,799	3,770	3,357	3,073	3,845	3,349	3,448	3,159
Market Capitalization	2,526	2,590	1,684	1,633	1,239	994	1,570	1,332	1,510	1,281
Book Value per Share	$16.02	$15.97	$15.95	$16.25	$12.73	$10.69	$11.00	$11.15	$11.28	$11.68
Tangible Book Value per Share	($11.47)	($11.56)	($11.36)	($11.29)	($10.61)	($10.24)	($10.39)	($10.10)	($9.70)	($8.99)
Total Capital	4,381	4,346	4,377	4,363	3,907	3,615	3,816	3,573	3,554	3,559
Total Debt	2,221	2,188	2,209	2,176	2,167	2,148	2,345	2,080	2,030	1,981
Total Long-Term Debt	2,162	2,153	2,169	2,136	2,127	2,095	2,264	2,040	2,014	1,965
Net Debt	2,110	2,142	2,108	2,130	2,111	2,071	2,266	2,011	1,930	1,871
Capital Expenditures (CapEx)	94	143	89	83	77	89	88	81	60	77
Debt-free, Cash-free Net Working Capital (DFCFNWC)	113	118	61	105	121	88	164	61	47	95
Debt-free Net Working Capital (DFNWC)	224	164	162	150	177	165	244	130	147	205
Net Working Capital (NWC)	165	129	122	110	137	112	163	90	131	189
Net Nonoperating Expense (NNE)	23	-12	13	25	130	101	-9.08	18	24	20
Net Nonoperating Obligations (NNO)	2,110	2,141	2,106	2,126	2,105	2,043	2,266	1,977	1,893	1,788
Total Depreciation and Amortization (D&A)	94	104	95	101	99	94	94	93	92	92
Debt-free, Cash-free Net Working Capital to Revenue	3.91%	3.97%	2.02%	3.42%	3.87%	2.76%	5.06%	1.86%	1.44%	2.92%
Debt-free Net Working Capital to Revenue	7.74%	5.52%	5.39%	4.89%	5.67%	5.17%	7.51%	4.00%	4.51%	6.29%
Net Working Capital to Revenue	5.70%	4.35%	4.06%	3.59%	4.38%	3.50%	5.03%	2.77%	4.01%	5.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.03)	$0.11	$0.10	($3.37)	($1.90)	($0.02)	$0.13	$0.16	$0.35
Adjusted Weighted Average Basic Shares Outstanding	134.23M	134.18M	134.53M	134.30M	134.83M	134.16M	132.91M	133.22M	134.30M	133.76M
Adjusted Diluted Earnings per Share	$0.11	$0.05	($0.06)	$0.09	($3.43)	($1.91)	($0.02)	$0.13	$0.15	$0.35
Adjusted Weighted Average Diluted Shares Outstanding	137.58M	138.99M	135.98M	136.23M	134.98M	134.42M	132.91M	136.03M	136.53M	135.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	134.73M	135.45M	134.17M	136.11M	136.39M	132.91M	133.20M	134.47M	134.55M	134.87M
Normalized Net Operating Profit after Tax (NOPAT)	40	19	18	40	36	71	40	43	47	71
Normalized NOPAT Margin	5.29%	2.40%	2.46%	5.03%	4.43%	8.25%	5.04%	5.37%	5.89%	8.29%
Pre Tax Income Margin	3.01%	0.41%	2.01%	2.58%	-60.63%	-31.66%	0.69%	3.45%	3.97%	8.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.80	0.00	1.47	1.63	-14.09	0.00	1.17	1.84	1.95	0.00
NOPAT to Interest Expense	1.40	0.00	0.91	1.23	-9.99	0.00	-0.31	1.16	1.41	0.00
EBIT Less CapEx to Interest Expense	-1.50	0.00	-1.32	-0.91	-16.48	0.00	-1.54	-0.62	0.18	0.00
NOPAT Less CapEx to Interest Expense	-1.90	0.00	-1.88	-1.31	-12.38	0.00	-3.02	-1.30	-0.36	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	2.04%	2.73%	0.00%	5.28%	-0.59%	-0.37%	0.00%	-0.51%	-1.67%	5.91%
Augmented Payout Ratio	16.29%	21.87%	48.80%	47.16%	-2.77%	-4.71%	-2.90%	-3.43%	-11.20%	5.91%

Frequently Asked Questions About AdaptHealth's Financials

When does AdaptHealth's fiscal year end?

According to the most recent income statement we have on file, AdaptHealth's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AdaptHealth's net income changed over the last 6 years?

AdaptHealth's net income appears to be on an upward trend, with a most recent value of $94.78 million in 2024, rising from $24.34 million in 2018. The previous period was -$674.78 million in 2023.

What is AdaptHealth's operating income?

AdaptHealth's total operating income in 2024 was $263.73 million, based on the following breakdown:

Total Gross Profit: $681.09 million
Total Operating Expenses: $417.36 million

How has AdaptHealth revenue changed over the last 6 years?

Over the last 6 years, AdaptHealth's total revenue changed from $361.05 million in 2018 to $3.26 billion in 2024, a change of 803.2%.

How much debt does AdaptHealth have?

AdaptHealth's total liabilities were at $2.91 billion at the end of 2024, a 4.4% decrease from 2023, and a 1,015,875.4% increase since 2017.

How much cash does AdaptHealth have?

In the past 7 years, AdaptHealth's cash and equivalents has ranged from $119.82 thousand in 2017 to $149.63 million in 2021, and is currently $109.75 million as of their latest financial filing in 2024.

How has AdaptHealth's book value per share changed over the last 6 years?

Over the last 6 years, AdaptHealth's book value per share changed from 0.00 in 2018 to 11.68 in 2024, a change of 1,167.7%.

Related Companies

This page (NASDAQ:AHCO) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AdaptHealth (AHCO) Financials

Frequently Asked Questions About AdaptHealth's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AdaptHealth (AHCO) Financials

Annual Income Statements for AdaptHealth

Quarterly Income Statements for AdaptHealth

Annual Cash Flow Statements for AdaptHealth

Quarterly Cash Flow Statements for AdaptHealth

Annual Balance Sheets for AdaptHealth

Quarterly Balance Sheets for AdaptHealth

Annual Metrics and Ratios for AdaptHealth

Quarterly Metrics and Ratios for AdaptHealth

Frequently Asked Questions About AdaptHealth's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools